FDA.reportPublic FDA data

CUVITRU 20 % per 50 ML Injection

RxCUI
2117971
RxNorm name
CUVITRU 20 % per 50 ML Injection
Display name
CUVITRU 20 % per 50 ML Injection
Full name
CUVITRU 20 % per 50 ML Injection
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:10

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125596CuvitruImmune Globulin Subcutaneous (Human), 20% Solution351(a)Rx2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
9aad7ec9-6097-4805-8f1b-898bec35f218CUVITRU 20 % per 50 ML InjectionSY19These highlights do not include all the information needed to use CUVITRU ® safely and effectively. See full prescribing information for CUVITRU. CUVITRU ® , Immune Globulin Subcutaneous (Human), 20% Solution Initial U.S. Approval: 201620251125
9aad7ec9-6097-4805-8f1b-898bec35f21850 ML Cuvitru 200 MG/ML InjectionSY19These highlights do not include all the information needed to use CUVITRU ® safely and effectively. See full prescribing information for CUVITRU. CUVITRU ® , Immune Globulin Subcutaneous (Human), 20% Solution Initial U.S. Approval: 201620251125
9aad7ec9-6097-4805-8f1b-898bec35f218CUVITRU 20 % in 50 ML InjectionPSN19These highlights do not include all the information needed to use CUVITRU ® safely and effectively. See full prescribing information for CUVITRU. CUVITRU ® , Immune Globulin Subcutaneous (Human), 20% Solution Initial U.S. Approval: 201620251125
9aad7ec9-6097-4805-8f1b-898bec35f21850 ML immunoglobulin G, human 200 MG/ML Injection [Cuvitru]SBD19These highlights do not include all the information needed to use CUVITRU ® safely and effectively. See full prescribing information for CUVITRU. CUVITRU ® , Immune Globulin Subcutaneous (Human), 20% Solution Initial U.S. Approval: 201620251125